Clene Nanomedicine Announces First Patient Enrolled in the REPAIR-PD Clinical Trial for the Treatment of Parkinson’s Disease with the Nanocatalytic Therapeutic, CNM-Au8

SALT LAKE CITY, Dec. 3, 2019 /PRNewswire/ — Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the dosing of the first participant enrolled in the REPAIR-PD study with its lead nanocatalytic therapy, CNM-Au8, for the treatment...
SEARCH FOR STUDIES